Top-Rated StocksTop-RatedNASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free BBIO Stock Alerts $27.86 -1.14 (-3.93%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$27.47▼$28.5550-Day Range$24.33▼$31.0452-Week Range$14.78▼$44.32Volume1.13 million shsAverage Volume1.63 million shsMarket Capitalization$5.21 billionP/E RatioN/ADividend YieldN/APrice Target$47.62 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BridgeBio Pharma alerts: Email Address BridgeBio Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside70.9% Upside$47.62 Price TargetShort InterestBearish11.87% of Float Sold ShortDividend StrengthN/ASustainability-2.31Upright™ Environmental ScoreNews Sentiment0.49Based on 10 Articles This WeekInsider TradingSelling Shares$28,840 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.20) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.41 out of 5 starsMedical Sector108th out of 915 stocksPharmaceutical Preparations Industry41st out of 430 stocks 4.5 Analyst's Opinion Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.87% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in BridgeBio Pharma has recently increased by 5.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBridgeBio Pharma has received a 53.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Infigratinib", "Fosdenopterin", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for BridgeBio Pharma is -2.31. Previous Next 3.0 News and Social Media Coverage News SentimentBridgeBio Pharma has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BridgeBio Pharma this week, compared to 5 articles on an average week.Search Interest16 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows6 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,840.00 in company stock.Percentage Held by Insiders24.66% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.20) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -8.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BridgeBio Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. About BridgeBio Pharma Stock (NASDAQ:BBIO)BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Read More BBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBIO Stock News HeadlinesJune 6, 2024 | insidertrades.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Sells 1,000 Shares of StockJune 13 at 2:38 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJune 12 at 10:00 AM | businesswire.comBridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJune 10, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJune 7, 2024 | americanbankingnews.comRandal W. Scott Sells 1,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockJune 7, 2024 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Forecasted to Earn FY2025 Earnings of ($0.48) Per ShareJune 6, 2024 | globenewswire.comBridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare ConferenceJune 6, 2024 | businesswire.comBridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRASG12C NSCLCJune 6, 2024 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $28.98June 5, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOJune 5, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in June 2024June 5, 2024 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Receives Buy Rating from HC WainwrightJune 4, 2024 | globenewswire.comBridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for HypochondroplasiaJune 3, 2024 | globenewswire.comBridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024June 3, 2024 | seekingalpha.comBridgeBio Pharma: Upping An Existing Position (Rating Upgrade)May 29, 2024 | finance.yahoo.comAdditional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 29, 2024 | globenewswire.comAdditional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)May 28, 2024 | markets.businessinsider.comBuy Rating Affirmed on BridgeBio Pharma Amid Promising ATTRibute-CM Study ResultsMay 27, 2024 | investorplace.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 24, 2024 | globenewswire.comBridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingMay 22, 2024 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings ForecastsMay 16, 2024 | markets.businessinsider.comPromising Clinical Data Bolsters Buy Rating for BridgeBio PharmaMay 16, 2024 | benzinga.comBridgeBio Pharma's Options: A Look at What the Big Money is ThinkingMay 15, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/15/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BBIO CUSIPN/A CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees550Year FoundedN/APrice Target and Rating Average Stock Price Target$47.62 High Stock Price Target$70.00 Low Stock Price Target$33.00 Potential Upside/Downside+70.9%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-643,200,000.00 Net Margins-246.24% Pretax Margin-250.09% Return on EquityN/A Return on Assets-80.12% Debt Debt-to-Equity RatioN/A Current Ratio5.54 Quick Ratio5.54 Sales & Book Value Annual Sales$9.30 million Price / Sales560.59 Cash FlowN/A Price / Cash FlowN/A Book Value($7.72) per share Price / Book-3.61Miscellaneous Outstanding Shares187,130,000Free Float140,983,000Market Cap$5.21 billion OptionableOptionable Beta1.08 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Neil Kumar Ph.D. (Age 45)Co-Founder, President, CEO & Director Comp: $1.53MDr. Charles J. Homcy M.D. (Age 76)Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Comp: $563.2kDr. Frank P. McCormick Ph.D. (Age 74)Co-Founder, Chairman of Oncology & Director Comp: $542.78kDr. Brian C. Stephenson C.F.A. (Age 43)Ph.D., CFO & Secretary Comp: $1.15MDr. Richard H. Scheller Ph.D. (Age 71)Chairman of Research & Development Comp: $509.62kDr. Uma Sinha Ph.D. (Age 66)Chief Scientific Officer Comp: $1.31MGrace RauhVice President of CommunicationsMr. Eli M. Wallace Ph.D. (Age 57)Chief Scientific Officer of Oncology Dr. Thomas Trimarchi Ph.D.Chief Product OfficerDr. Eric Michael David J.D. (Age 52)M.D., Ph.D., Chief Executive Officer of Gene Therapy More ExecutivesKey CompetitorsTurning Point TherapeuticsNASDAQ:TPTXReata PharmaceuticalsNASDAQ:RETAArrowhead PharmaceuticalsNASDAQ:ARWRBiohavenNYSE:BHVNSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsRandal W ScottSold 1,000 sharesTotal: $28,840.00 ($28.84/share)Zimmer Partners LPBought 8,200 shares on 5/17/2024Ownership: 0.039%Comerica BankBought 37,277 shares on 5/17/2024Ownership: 0.021%Walleye Trading LLCBought 7,300 shares on 5/17/2024Ownership: 0.000%Jane Street Group LLCBought 181,500 shares on 5/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions BBIO Stock Analysis - Frequently Asked Questions Should I buy or sell BridgeBio Pharma stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BBIO shares. View BBIO analyst ratings or view top-rated stocks. What is BridgeBio Pharma's stock price target for 2024? 12 analysts have issued 1 year price objectives for BridgeBio Pharma's stock. Their BBIO share price targets range from $33.00 to $70.00. On average, they anticipate the company's share price to reach $47.62 in the next year. This suggests a possible upside of 70.9% from the stock's current price. View analysts price targets for BBIO or view top-rated stocks among Wall Street analysts. How have BBIO shares performed in 2024? BridgeBio Pharma's stock was trading at $40.37 on January 1st, 2024. Since then, BBIO shares have decreased by 31.0% and is now trading at $27.86. View the best growth stocks for 2024 here. Are investors shorting BridgeBio Pharma? BridgeBio Pharma saw a increase in short interest in May. As of May 31st, there was short interest totaling 16,630,000 shares, an increase of 5.4% from the May 15th total of 15,780,000 shares. Based on an average daily volume of 1,600,000 shares, the days-to-cover ratio is currently 10.4 days. Approximately 11.9% of the shares of the stock are sold short. View BridgeBio Pharma's Short Interest. When is BridgeBio Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our BBIO earnings forecast. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.35. The firm had revenue of $211.12 million for the quarter, compared to analysts' expectations of $140.06 million. What ETFs hold BridgeBio Pharma's stock? ETFs with the largest weight of BridgeBio Pharma (NASDAQ:BBIO) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Franklin Genomic Advancements ETF (HELX), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal U.S. Small-Cap Multi-Factor ETF (PSC). What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT). When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $225 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? BridgeBio Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.07%), Janus Henderson Group PLC (1.77%), Capital Research Global Investors (1.18%), Hhlr Advisors LTD. (0.73%), Principal Financial Group Inc. (0.57%) and Price T Rowe Associates Inc. MD (0.43%). Insiders that own company stock include Brian C Stephenson, Douglas A Dachille, Frank Mccormick, Global Investors Lp Viking, Hannah Valantine, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BBIO) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.